David Ryan, MD
Medical Oncology · Boston, MANPI 1184605594
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,055 of the $4,055 with a category attached, or 100.0%. Innocoll Pharmaceuticals Limited accounts for 64.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $2,600 and has fallen 97.9% since, to $55 in 2023. That places this record below the midpoint for medical oncology clinicians in MA, where the typical reported total is $2,567.
Across 3 payments — averaging $1351.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Innocoll Pharmaceuticals Limited$3K
- Pfizer$1K
- Exact Sciences$55
Across 38 payments — averaging $10,499 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$171K
- Genentech, Inc.$124K
- Astrazeneca UK Limited$87K
- Amgen$17K
- Novartis$252
- Pfizer$250
What the payments were for
- Speaking & faculty fees$4,055100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Innocoll Pharmaceuticals Limited | 1 | $2,600 |
| Pfizer | 1 | $1,400 |
| Exact Sciences | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARACOLL$2,600
How this compares
$4,055 in reported general payments places this provider in the 50th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,400 | $6,43911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.